疏肝健脾汤对早期乙肝肝硬化患者血清炎性因子的影响

发布时间：2018-06-14 10:54

  本文选题：疏肝健脾汤 + 乙肝肝硬化　； 参考：《中药材》2017年04期

【摘要】：目的:观察疏肝健脾汤治疗早期乙肝肝硬化肝气郁结证患者的临床疗效及对患者血清IL-21、IL-22、IL-31及TGF-β1的影响。方法:将106例早期乙肝肝硬化肝气郁结证患者随机分为对照组和观察组各53例。对照组给予恩替卡韦治疗,观察组在对照组的治疗上加用疏肝健脾汤,所有患者均接受6个月的治疗。检测两组患者治疗前后血清丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、血清白蛋白(ALB)、透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原肽(PⅢNP)、Ⅳ型胶原(COLⅣ)、白介素21(IL-21)、白介素22(IL-22)、白介素31(IL-31)和转化生长因子β1(TGF-β1)水平及肝纤维化模型Fibro Test(FT)参数。结果:两组患者治疗后血清ALT、AST、TBIL、HA、LN、PⅢNP、COLⅣ、IL-21、IL-22、IL-31及TGF-β1水平均显著降低,ALB水平显著升高,FT参数显著降低(P0.05);且观察组以上指标改善均显著优于对照组(P0.05)。结论:疏肝健脾汤治疗早期乙肝肝硬化肝气郁结证的机制可能与降低患者血清炎症因子IL-21、IL-22、IL-31及TGF-β1水平有关。
[Abstract]:Objective: to observe the clinical effect of Shugan Jianpi decoction (Shugan Jianpi decoction) in the treatment of liver qi stagnation syndrome of early hepatitis B cirrhosis and the effect of Shugan Jianpi decoction on serum IL-21 and TGF- 尾 1 levels. Methods: 106 patients with liver qi stagnation syndrome of early hepatitis B cirrhosis were randomly divided into control group (53 cases) and observation group (53 cases). The control group was treated with entecavir, the observation group was treated with Shugan Jianpi decoction, all the patients were treated for 6 months. Serum alanine aminotransferase (alt), aspartate aminotransferase (AST), total bilirubin (TBILL), serum albumin (Albumin), hyaluronic acid (HA), laminin (LN), type 鈪，

本文编号：2017139